{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '133', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'and accidental trauma (eg, sprained ankle) that may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', 'e. Is a congenital anomaly/birth defect', 'In offspring of participant taking the product regardless of time to diagnosis.', 'f.', 'Other important medical events', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that may', 'not be immediately life-threatening or result in death or hospitalization but may', 'jeopardize the participant or may require medical or surgical intervention to prevent 1', 'of the other outcomes listed in the above definition. These events should usually be', 'considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment in', 'an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', '10.3.3', 'Additional Events Reported in the Same Manner as SAE', 'Additional events that require reporting in the same manner as SAE', 'In addition to the above criteria, AEs meeting either of the below criteria, although not', 'serious per ICH definition, are reportable to the Sponsor in the same time frame as SAEs to', 'meet certain local requirements. Therefore, these events are considered serious by the', 'Sponsor for collection purposes.', 'Is a new cancer (that is not a condition of the study)', 'Is associated with an overdose of pembrolizumab', '10.3.4', 'Recording AE and SAE', 'AE and SAE recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to', 'the event.', 'The investigator will record all relevant AE/SAE information on the AE', 'CRFs/worksheets at each examination.', \"It is not acceptable for the investigator to send photocopies of the participant's medical\", 'records to the Sponsor in lieu of completion of the AE CRF page.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '134', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'There may be instances when copies of medical records for certain cases are requested by', 'the Sponsor. In this case, all participant identifiers, with the exception of the participant', 'number, will be blinded on the copies of the medical records before submission to the', 'Sponsor.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. In such cases, the diagnosis (not the', 'individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of intensity/toxicity', 'An event is defined as \"serious\" when it meets at least 1 of the predefined outcomes as', 'described in the definition of an SAE, not when it is rated as severe.', '1.', 'The investigator will make an assessment of intensity for each AE and SAE (and', 'other reportable safety event) according to the NCI Common Terminology for', 'Adverse Events (CTCAE), version 4. Any AE that changes CTCAE grade over the', 'course of a given episode will have each change of grade recorded on the AE', 'CRFs/worksheets.', '-', 'Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic', 'observations only; intervention not indicated.', '- Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting', 'age-appropriate instrumental activities of daily living (ADL).', '-', 'Grade 3: Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting', 'self-care ADL.', '-', 'Grade 4: Life threatening consequences; urgent intervention indicated.', '-', 'Grade 5: Death related to AE.', 'Assessment of causality', '1.', \"Did the Sponsor's product cause the AE?\", '2.', \"The determination of the likelihood that the Sponsor's product caused the AE will be\", \"provided by an investigator who is a qualified physician. The investigator's\", 'signed/dated initials on the source document or worksheet that supports the causality', 'noted on the AE form, ensures that a medically qualified assessment of causality was', 'done. This initialed document must be retained for the required regulatory time frame.', 'The criteria below are intended as reference guidelines to assist the investigator in', 'assessing the likelihood of a relationship between the test product and the AE based', 'upon the available information.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}